Free Trial

Extendicare Inc. (TSE:EXE) Stock Has Consensus Target Price of C$37.00

Extendicare logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is unanimously positive: All seven covering firms rate Extendicare a Buy, with an average 12-month price target of C$37.00.
  • Recent target changes were mixed: Canaccord raised its target to C$44, while Desjardins and National Bank Financial cut theirs; RBC lifted its target to C$39.
  • Extendicare reported quarterly EPS of C$0.41 on C$627.84 million in revenue and declared a monthly dividend of C$0.0441 per share, equivalent to an annualized yield of about 1.9%.
  • MarketBeat previews top five stocks to own in December.

Extendicare Inc. (TSE:EXE - Get Free Report) has earned a consensus rating of "Buy" from the seven ratings firms that are covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is C$37.00.

EXE has been the topic of a number of recent research reports. Desjardins dropped their target price on Extendicare from C$40.00 to C$39.00 and set a "buy" rating on the stock in a research report on Monday, August 10th. Royal Bank Of Canada increased their target price on shares of Extendicare from C$38.00 to C$39.00 and gave the stock an "outperform" rating in a report on Friday, August 14th. Canaccord Genuity Group lifted their target price on Extendicare from C$37.00 to C$44.00 and gave the company a "buy" rating in a research report on Monday, August 10th. Finally, National Bank Financial dropped their target price on Extendicare from C$45.00 to C$40.00 and set an "outperform" rating on the stock in a report on Wednesday, October 21st.

Get Our Latest Stock Analysis on Extendicare

Extendicare Stock Performance

Shares of TSE:EXE opened at C$27.61 on Friday. The business has a fifty day moving average of C$28.92 and a 200-day moving average of C$30.02. The company has a debt-to-equity ratio of 159.54, a quick ratio of 0.98 and a current ratio of 0.75. Extendicare has a twelve month low of C$15.80 and a twelve month high of C$39.14. The firm has a market cap of C$2.62 billion, a PE ratio of 21.14 and a beta of 1.31.

Extendicare (TSE:EXE - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported C$0.41 earnings per share (EPS) for the quarter. The firm had revenue of C$627.84 million for the quarter. Extendicare had a return on equity of 36.33% and a net margin of 6.13%. On average, equities research analysts predict that Extendicare will post 0.61 EPS for the current fiscal year.

Extendicare Dividend Announcement

The business also recently declared a monthly dividend, which will be paid on Monday, November 16th. Shareholders of record on Monday, November 16th will be given a dividend of $0.0441 per share. The ex-dividend date of this dividend is Friday, October 30th. This represents a $0.53 annualized dividend and a dividend yield of 1.9%. Extendicare's payout ratio is 39.23%.

About Extendicare

(Get Free Report)

Extendicare is a leading provider of care and services for seniors across Canada, operating under the Extendicare, ParaMed, Extendicare Assist, and SGP Purchasing Network brands. We are committed to delivering quality care to meet the needs of the growing seniors' population, inspired by our mission to provide people with the care they need, wherever they call home. We deliver more than 27 million hours of home health care services annually, operate a network of 97 long-term care homes (58 owned, 39 under management contracts), and provide group purchasing services to third parties representing approximately 161,700 beds across Canada.

Featured Stories

Analyst Recommendations for Extendicare (TSE:EXE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Extendicare Right Now?

Before you consider Extendicare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Extendicare wasn't on the list.

While Extendicare currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines